Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

Matthew S Block; Garth D Nelson; Jun Chen; Stephen Johnson; Lu Yang; Thomas James Flotte; Eric P Grewal; Robert R McWilliams; Lisa A Kottschade; Evidio Domingo-Musibay; Svetomir N Markovic; Anastasios Dimou; Heather N Montane; Mara A Piltin; Daniel L Price; Samir S Khariwala; Jane Yuet Ching Hui; Courtney L Erskine; Carrie A Strand; David Zahrieh; Haidong Dong; Tina J Hieken

doi:10.1136/jitc-2025-011706

Article info

Immunotherapy biomarkers

Original research

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

Authors

Matthew S Block Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Garth D Nelson Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Jun Chen Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Stephen Johnson Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Lu Yang Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Thomas James Flotte Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Eric P Grewal Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Robert R McWilliams Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Lisa A Kottschade Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Evidio Domingo-Musibay Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA PubMed articles Google scholar articles
Svetomir N Markovic Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Anastasios Dimou Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Heather N Montane Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Mara A Piltin Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Daniel L Price Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Samir S Khariwala Department of Otolaryngology, University of Minnesota, Minneapolis, Minnesota, USA PubMed articles Google scholar articles
Jane Yuet Ching Hui Division of Surgical Oncology, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA PubMed articles Google scholar articles
Courtney L Erskine Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Carrie A Strand Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
David Zahrieh Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Haidong Dong Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles
Tina J Hieken Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA PubMed articles Google scholar articles

Correspondence to Dr Tina J Hieken; Hieken.tina{at}mayo.edu

View Full Text

Citation

Block MS, Nelson GD, Chen J, et al

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

Journal for ImmunoTherapy of Cancer 2025;13:e011706. doi: 10.1136/jitc-2025-011706

Publication history

Accepted April 1, 2025
First published April 15, 2025.

Online issue publication

April 15, 2025

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password